Business Description
Consun Pharmaceutical Group Ltd
ISIN : KYG2524A1031
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.01 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | 0.54 | |||||
Interest Coverage | 32.36 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.94 | |||||
Beneish M-Score | -2.54 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.7 | |||||
3-Year EBITDA Growth Rate | 10.3 | |||||
3-Year EPS without NRI Growth Rate | 14.1 | |||||
3-Year FCF Growth Rate | -3.8 | |||||
3-Year Book Growth Rate | 16 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 13.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.56 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.3 | |||||
9-Day RSI | 49.94 | |||||
14-Day RSI | 51.09 | |||||
6-1 Month Momentum % | -32.31 | |||||
12-1 Month Momentum % | -27.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.86 | |||||
Quick Ratio | 2.62 | |||||
Cash Ratio | 2.4 | |||||
Days Inventory | 172.21 | |||||
Days Sales Outstanding | 24.75 | |||||
Days Payable | 39.16 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 11.8 | |||||
Dividend Payout Ratio | 0.4 | |||||
3-Year Dividend Growth Rate | 33.2 | |||||
Forward Dividend Yield % | 11.8 | |||||
5-Year Yield-on-Cost % | 32.42 | |||||
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | 9.96 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 74.21 | |||||
Operating Margin % | 32.39 | |||||
Net Margin % | 30.53 | |||||
FCF Margin % | 28.05 | |||||
ROE % | 24.57 | |||||
ROA % | 16.04 | |||||
ROIC % | 35.33 | |||||
3-Year ROIIC % | -155.54 | |||||
ROC (Joel Greenblatt) % | 115.25 | |||||
ROCE % | 24.89 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 4.79 | |||||
Forward PE Ratio | 4.35 | |||||
PE Ratio without NRI | 4.74 | |||||
Shiller PE Ratio | 8.87 | |||||
Price-to-Owner-Earnings | 5.29 | |||||
PEG Ratio | 0.25 | |||||
PS Ratio | 1.46 | |||||
PB Ratio | 1.08 | |||||
Price-to-Tangible-Book | 1.2 | |||||
Price-to-Free-Cash-Flow | 5.14 | |||||
Price-to-Operating-Cash-Flow | 4.81 | |||||
EV-to-EBIT | 1.33 | |||||
EV-to-EBITDA | 1.33 | |||||
EV-to-Revenue | 0.46 | |||||
EV-to-FCF | 1.29 | |||||
Price-to-Projected-FCF | 0.36 | |||||
Price-to-DCF (Earnings Based) | 0.19 | |||||
Price-to-DCF (FCF Based) | 0.14 | |||||
Price-to-Median-PS-Value | 0.65 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.27 | |||||
Price-to-Graham-Number | 0.52 | |||||
Price-to-Net-Current-Asset-Value | 1.62 | |||||
Price-to-Net-Cash | 2.31 | |||||
Earnings Yield (Greenblatt) % | 75.36 | |||||
FCF Yield % | 17.67 | |||||
Forward Rate of Return (Yacktman) % | 35.46 |